.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Medtronic
Baxter
Fuji
Accenture
Johnson and Johnson
Cerilliant
Federal Trade Commission
Covington
QuintilesIMS

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091613

« Back to Dashboard
NDA 091613 describes NAFCILLIN SODIUM, which is a drug marketed by Istituto Bio Ita Spa, Mylan Labs Ltd, Watson Labs Inc, Aurobindo Pharma Ltd, Sandoz, Antibiotice, Sagent Pharms, and Apothecon, and is included in thirteen NDAs. It is available from seven suppliers. Additional details are available on the NAFCILLIN SODIUM profile page.

The generic ingredient in NAFCILLIN SODIUM is nafcillin sodium. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the nafcillin sodium profile page.

Summary for NDA: 091613

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 091613

Ingredient-typePenicillins

Suppliers and Packaging for NDA: 091613

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NAFCILLIN SODIUM
nafcillin sodium
 INJECTABLE;INJECTION 091613 ANDA AuroMedics Pharma LLC 55150-122 55150-122-15 10 VIAL in 1 BOX (55150-122-15) > 4 mL in 1 VIAL
NAFCILLIN SODIUM
nafcillin sodium
 INJECTABLE;INJECTION 091613 ANDA AuroMedics Pharma LLC 55150-123 55150-123-15 10 VIAL in 1 BOX (55150-123-15) > 8 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1GM BASE/VIAL
Approval Date:Dec 26, 2012TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2GM BASE/VIAL
Approval Date:Dec 26, 2012TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Dow
McKesson
Chinese Patent Office
Novartis
McKinsey
Accenture
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot